Ubiquinone and glycaemic measures in type 1 diabetes

Editorial study summary

Study type

Randomized, double-blind, placebo-controlled human trial.

Product relevance

Ingredient evidence for ubiquinone, the oxidized form of CoQ10. The trial did not test the DR.MORGAN formula.

Sample or population

34 patients with type 1 diabetes.

Studied dose

100 mg/day of ubiquinone or placebo.

Duration

3 months.

Finding

Serum CoQ10 increased with ubiquinone. There were no between-group differences in glycaemic measures, insulin dose, hypoglycaemic episodes, cholesterol or reported well-being.

Limitations

The study was small and disease-specific. It does not establish general safety or support changes to diabetes care.

Study quality

Randomized comparison of blood measures, insulin use and patient-reported outcomes. Editorial review was limited to the abstract. No formal risk-of-bias rating was assigned.

Funding and disclosures

Funding and conflicts were not verified from the abstract.

The studies discussed here examine ingredients or other formulations. They do not establish results for this DR.MORGAN finished product.

Reference

1. Impact of ubiquinone (coenzyme Q10) treatment on glycaemic control, insulin requirement and well-being in patients with Type 1 diabetes mellitus. Diabet Med. 1999. PMID 10220205